Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
Conditions
Glaucoma
Interventions
HOCD
Device
Lead sponsor
Benjamin Frankfort, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional

iCare HOME2 Clinical Trial

NCT05162989
Conditions
Intraocular Pressure, Glaucoma
Interventions
iCare HOME2 vs iCare IC200
Device
Lead sponsor
Icare Finland Oy
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Results available

Steroids After Laser Trabeculoplasty for Glaucoma

NCT00981435
Conditions
Glaucoma
Interventions
Prednisolone 1%, Ketorolac, Artificial Tears
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Miami, Florida • Pittsburgh, Pennsylvania
Conditions
Retinal Disease, Glaucoma
Interventions
P200TE, Spectral OCT/SLO
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

NCT02167035
Conditions
Glaucoma, Ocular Hypertension
Interventions
Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Conditions
Open-Angle Glaucoma
Interventions
iStent plus Cataract Surgery, Cataract surgery only
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
31
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 27 more
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Conditions
Open-Angle Glaucoma
Interventions
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Procedure
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Mesa, Arizona
Conditions
Glaucoma
Interventions
0.005% Latanoprost dosed once.
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Not listed Not applicable Interventional Accepts healthy volunteers

The International Collaborative Exfoliation Syndrome Treatment Study

NCT00804115
Conditions
Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or Cosopt
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Conditions
Glaucoma
Interventions
Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Glaucoma, Eye Disorders, Visual Fields, Visual Field Tests
Interventions
LLM-based Education
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Glaucoma
Interventions
App
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Glaucoma
Interventions
bevacizumab, balanced salt solution
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

Optimize Pediatric OCT Imaging

NCT06139523
Conditions
Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Investigational contact OCT system, Investigational noncontact OCT system:
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
6 participants
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado